IL6 and congenital rubella syndrome: It is encouraging that our results of initial 18 patients clearly demonstrated that CART-secreted aIL6 scFv and IL1RA could efficiently restrain IL6 and IL1 elevation during CRS, therefore minimizing IL6- and IL1-associated toxicity during CART therapy.